A Phase 1/2 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway

Trial Profile

A Phase 1/2 Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Miransertib (Primary)
  • Indications Growth disorders; Proteus syndrome
  • Focus Adverse reactions
  • Sponsors ArQule
  • Most Recent Events

    • 01 Nov 2017 According to an ArQule media release, phase 1 portion of the trial is enrolling six patients in a dose escalation cohort and additional 10 patients will be enrolled in an expansion cohort as part of the phase 2 portion of the trial.
    • 07 Jun 2017 According to an ArQule Inc, media release, the first patient has been dosed in this trial.
    • 03 May 2017 According to an ArQule Inc, media release, the first patient has been identified in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top